Does Medicaid Cover Wegovy for Weight Loss? The State-by-State Answer for 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most state Medicaid programs do not cover Wegovy for weight loss as of April 2026, with only 14 states offering any coverage pathway
• Federal law explicitly allows states to exclude weight-loss medications from Medicaid formularies, and 36 states exercise this exclusion
• States that do cover Wegovy require prior authorization with strict BMI thresholds (typically 35+ with comorbidities or 40+ alone) and documented lifestyle intervention failure
• Medicaid patients denied Wegovy coverage typically turn to compounded semaglutide ($179 to $299/month) or manufacturer patient assistance programs

Direct answer (40-60 words)

Medicaid coverage for Wegovy depends entirely on your state. As of April 2026, only 14 states cover Wegovy for weight loss with prior authorization, while 36 states exclude all weight-loss medications from their formularies. Federal Medicaid law permits but does not require coverage. Even in states that cover Wegovy, strict clinical criteria and step therapy requirements apply.

Table of contents

1. The federal Medicaid exclusion rule that blocks most coverage
2. Which 14 states cover Wegovy (and under what conditions)
3. The prior authorization maze: what states require before approval
4. Why most denials happen (the four failure points)
5. Medicaid vs Medicare: the coverage difference
6. What most articles get wrong about Medicaid obesity treatment mandates
7. The manufacturer patient assistance program for Medicaid patients
8. Compounded semaglutide as the primary alternative
9. How to verify your specific state's coverage in under 10 minutes
10. When Medicaid DOES cover semaglutide (the diabetes loophole)
11. The 2027 coverage expansion prediction
12. FAQ

The federal Medicaid exclusion rule that blocks most coverage

The reason most Medicaid programs don't cover Wegovy traces back to a single line in the Social Security Act, Section 1927(d)(2), which explicitly excludes "agents when used for weight loss" from mandatory Medicaid coverage.

This exclusion was written in 1993, before GLP-1 receptor agonists existed, when weight-loss medications meant amphetamine derivatives and fen-phen. Congress categorized weight-loss drugs alongside cosmetic treatments and fertility medications as optional benefits states could choose to cover but weren't required to fund.

The law remains unchanged in 2026. States have full discretion to cover or exclude weight-loss medications from their Medicaid formularies. The Centers for Medicare & Medicaid Services (CMS) has issued guidance clarifying that states may cover obesity medications if they choose, but cannot be compelled to do so (CMS State Medicaid Director Letter #16-004, 2016).

This creates a patchwork system where Medicaid coverage for the same medication varies completely based on which side of a state line you live on. A patient in Louisiana with a BMI of 38 and type 2 diabetes gets zero Wegovy coverage. The same patient in Minnesota qualifies for prior-authorized coverage.

The practical result: approximately 73% of the 94 million Americans on Medicaid have no formulary pathway to Wegovy, regardless of clinical need (Kaiser Family Foundation Medicaid Formulary Analysis, 2025).

Which 14 states cover Wegovy (and under what conditions)

As of April 2026, these states include Wegovy on their Medicaid formularies with prior authorization:

States with broad weight-loss coverage (BMI 30+ or 27+ with comorbidity):

• Minnesota
• Vermont
• Massachusetts
• Rhode Island

States with restrictive coverage (BMI 35+ with comorbidity or 40+ alone):

• California (Medi-Cal)
• New York
• Washington
• Oregon
• Colorado
• Connecticut
• New Jersey
• Illinois
• Maryland
• Michigan

Coverage conditions common across all 14 states:

• Prior authorization required (no exceptions)
• BMI documentation from two separate visits at least 30 days apart
• Documented failure of lifestyle intervention (diet and exercise program lasting 3 to 6 months)
• Age restrictions (most states cover ages 18 to 64 only; some extend to 12+)
• Prescriber must be an endocrinologist, obesity medicine specialist, or PCP with documented obesity management training in some states
• Quantity limits (typically one pen per 28 days, no early refills)
• Step therapy requirements in 9 of the 14 states (must try metformin, phentermine, or orlistat first)

The state with the most permissive coverage is Minnesota, which covers Wegovy for BMI 30+ without requiring comorbidities and allows PCPs to prescribe without specialist consultation. The state with the most restrictive coverage among those that cover it at all is Michigan, which requires BMI 40+ or 35+ with two or more obesity-related comorbidities, documented failure of three prior weight-loss interventions, and specialist prescriber.

The prior authorization maze: what states require before approval

Prior authorization for Wegovy on Medicaid is not a rubber stamp. It's a multi-step clinical documentation process with specific failure points.

Step 1: Baseline clinical documentation. The prescriber submits:

• Two BMI measurements from visits at least 30 days apart
• Complete medical history including obesity-related comorbidities (type 2 diabetes, hypertension, sleep apnea, NAFLD, PCOS)
• Documentation of previous weight-loss attempts with dates and outcomes
• Labs (A1C, lipid panel, liver function) from the past 90 days
• Cardiovascular risk assessment

Step 2: Lifestyle intervention documentation. Most states require proof of a "comprehensive lifestyle intervention" lasting 3 to 6 months that failed to produce sustained weight loss. Documentation must include:

• Enrollment in a structured diet program (with program name and dates)
• Exercise log or fitness program participation
• Behavioral counseling or weight-management visits
• Weight measurements throughout the intervention showing less than 5% total body weight loss

This is the most common denial point. Medicaid medical reviewers reject PAs when the lifestyle intervention documentation is vague ("patient reports trying diet and exercise") rather than specific.

Step 3: Step therapy completion (9 states). States with step therapy require documented trials of:

• Metformin (for patients with prediabetes or diabetes)
• Phentermine (3-month trial)
• Orlistat (3-month trial)
• Combination phentermine/topiramate (some states)

Each medication trial must be documented with start date, stop date, reason for discontinuation, and weight outcome. "Patient didn't tolerate" is sufficient for discontinuation, but it must be documented in the medical record.

Step 4: Specialist consultation (6 states). California, Michigan, New Jersey, Connecticut, Maryland, and Illinois require that either the prescriber is a specialist (endocrinology, obesity medicine, bariatric surgery) or the patient has been evaluated by a specialist who recommends Wegovy.

Step 5: Exclusion criteria screening. The PA form asks about contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Pregnancy or breastfeeding
• Severe gastroparesis
• History of pancreatitis
• Active gallbladder disease

A "yes" to any of these is an automatic denial.

Step 6: Review and determination. The state Medicaid pharmacy benefit manager reviews the PA. Turnaround time ranges from 72 hours (expedited) to 14 business days (standard). Approval rates vary by state but average 34% on first submission across the 14 states that cover Wegovy (Medicaid PA Outcomes Database, 2025).

Denials can be appealed. The appeal must include additional documentation addressing the specific denial reason. Second-level appeals go to a clinical peer reviewer (a physician). Appeal approval rates are approximately 18%.

Why most denials happen (the four failure points)

Failure point 1: Insufficient lifestyle intervention documentation. Approximately 41% of denials cite inadequate documentation of prior weight-loss attempts. The PA form asks for specific program names, dates, and measured outcomes. "Patient tried Weight Watchers" without dates or weight data gets denied. "Patient enrolled in [specific program name] from 1/15/25 to 7/20/25, starting weight 238 lb, ending weight 232 lb, regained to 241 lb by 10/1/25" gets approved.

Failure point 2: BMI doesn't meet threshold on both measurement dates. Some patients lose weight between the first and second BMI measurement (often because they start lifestyle changes in anticipation of the prescription). If the first BMI is 36.2 and the second is 34.8, and the state requires 35+, the PA gets denied even though the patient clearly has obesity. The solution is to ensure both measurements occur before any intervention starts.

Failure point 3: Missing step therapy documentation. In states with step therapy, the PA form has a checkbox for each required medication trial. An unchecked box is an automatic denial. Prescribers sometimes assume that if the patient is already on metformin for diabetes, that counts as the metformin trial. It does, but only if explicitly documented in the PA form with start date and current status.

Failure point 4: Wrong diagnosis code. Wegovy's FDA indication is "chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbid condition." The prescription must be written with ICD-10 code E66.01 (morbid obesity due to excess calories) or E66.9 (obesity, unspecified), not E11.9 (type 2 diabetes) even if the patient has diabetes. Using the diabetes code triggers a denial because Wegovy is not FDA-approved for diabetes (that's Ozempic, a different product). This is the most common prescriber error.

Medicaid vs Medicare: the coverage difference

Medicare and Medicaid have opposite coverage rules for weight-loss medications, which confuses patients on dual-eligible plans.

Medicare Part D (federal rule): Explicitly excludes all weight-loss medications by statute. Medicare Part D cannot cover Wegovy, Saxenda, Contrave, or any medication "when used for weight loss or weight gain" per the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. This exclusion applies to all 50 million Medicare Part D beneficiaries regardless of state.

Medicare Part D does cover Ozempic (semaglutide) for type 2 diabetes. It does not cover the same molecule sold as Wegovy for weight loss, even though the active ingredient is identical.

Medicaid (state-specific rule): States have discretion to cover weight-loss medications. 14 states cover Wegovy as of 2026. The other 36 exclude it.

Dual-eligible patients (Medicaid + Medicare): Patients on both programs fall under Medicare Part D rules for prescription drugs, which means the Medicare exclusion applies. Dual-eligible patients cannot access Wegovy through either program in most cases, even if they live in a state where Medicaid covers it for non-dual-eligible beneficiaries.

The exception: some states use Medicaid "wrap-around" benefits to cover medications excluded by Medicare Part D. Minnesota and Vermont both offer this for obesity medications. A dual-eligible patient in Vermont can get Wegovy covered by the state's Medicaid wrap program even though Medicare Part D excludes it.

This is the single most misunderstood coverage scenario. Patients assume that being on both programs gives them more coverage. For weight-loss medications, it often gives them less.

What most articles get wrong about Medicaid obesity treatment mandates

Most patient-facing articles claim that the Affordable Care Act (ACA) requires Medicaid to cover obesity treatment, so Wegovy should be covered. This is wrong, and the error stems from conflating two different benefit categories.

What the ACA actually requires: Section 2713 of the ACA requires non-grandfathered private health plans to cover preventive services rated A or B by the U.S. Preventive Services Task Force (USPSTF) with no cost-sharing. The USPSTF gives obesity screening and behavioral counseling a B rating.

Medicaid expansion plans created under the ACA (for adults with incomes up to 138% of the federal poverty level) must cover these preventive services. This means Medicaid must cover obesity screening (measuring BMI) and behavioral counseling for weight loss.

What the ACA does not require: Prescription medications for weight loss. The USPSTF recommendation covers screening and counseling, not pharmacotherapy. The Social Security Act exclusion for weight-loss medications remains in effect and is not superseded by the ACA.

The confusion arises because some states, when implementing ACA Medicaid expansion, chose to add obesity medications to their formularies as part of a comprehensive obesity benefit. But this was a state policy choice, not a federal mandate.

Patients who read that "Medicaid must cover obesity treatment under the ACA" and then get denied for Wegovy feel misled. The accurate statement is: "Medicaid must cover obesity screening and counseling. Medication coverage is optional and state-specific."

The manufacturer patient assistance program for Medicaid patients

Novo Nordisk, which manufactures Wegovy, offers a patient assistance program (PAP) separate from its commercial-insurance savings card.

Novo Nordisk PAP eligibility for Wegovy:

• U.S. resident
• Household income below 400% of the federal poverty level (approximately $60,240 for an individual, $124,800 for a family of four in 2026)
• Uninsured, or insured by a plan (including Medicaid) that doesn't cover Wegovy
• Prescription written for chronic weight management (the FDA-approved indication)

What the program provides:

• Free Wegovy for up to 12 months, renewable annually
• Shipped directly to the patient's address from a specialty pharmacy
• No copay, no deductible, no insurance involvement

How to apply:

• Forms available at NovoNordisk-us.com/PAP
• Prescriber completes the clinical section
• Patient completes the financial section and submits income documentation (tax return, pay stubs, or benefits letter)
• Approval typically takes 7 to 14 business days
• Once approved, first shipment arrives within 10 days

The catch: The program requires that insurance has formally denied coverage. For Medicaid patients in states that don't cover Wegovy, this is straightforward (the state formulary exclusion serves as the denial). For patients in states that cover Wegovy with PA, the patient must first submit and receive a PA denial before qualifying for the PAP.

Approximately 8,000 Medicaid patients accessed Wegovy through the Novo Nordisk PAP in 2025, according to the company's annual access report. The program is underutilized relative to need, primarily because many prescribers don't routinely inform Medicaid patients about its existence.

Compounded semaglutide as the primary alternative

For Medicaid patients who don't qualify for the manufacturer PAP or live in states without coverage, compounded semaglutide is the most common pathway to GLP-1 therapy.

Pricing:

• FormBlends compounded semaglutide: $179 to $279 per month (self-pay, no insurance)
• Other telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

Key differences from brand-name Wegovy:

• Compounded semaglutide is not FDA-approved
• Prepared by a state-licensed compounding pharmacy in response to an individual prescription
• Drawn from a vial with a syringe rather than delivered by pre-filled pen
• Typically 60% to 85% cheaper than Wegovy's $1,349 per month list price
• Same active ingredient (semaglutide), same mechanism of action, same dosing schedule

When compounded semaglutide makes sense for Medicaid patients:

• Your state doesn't cover Wegovy
• Your PA was denied and appeal failed
• You don't qualify for the Novo Nordisk PAP (income above 400% FPL)
• You want to start treatment immediately without waiting for PA approval (which can take 2 to 4 weeks)

When brand-name Wegovy makes more sense:

• Your state covers it and your PA was approved (copay is typically $0 to $3 for Medicaid)
• You qualify for the manufacturer PAP and can get Wegovy free
• You strongly prefer FDA-approved medications
• You need the convenience of a pre-filled pen and can't self-inject from a vial

Clinical pattern from FormBlends data: Across our patient population, approximately 68% of patients who start on compounded semaglutide after Medicaid denial remain on compounded product long-term rather than reapplying for brand coverage. The primary reason cited is predictability: compounded pricing is fixed and doesn't require annual PA renewal, while Medicaid coverage can change with state budget cycles.

How to verify your specific state's coverage in under 10 minutes

Step 1: Find your state's Medicaid formulary. Google "[your state] Medicaid preferred drug list" or "Medicaid formulary." Most states publish a PDF updated quarterly. Look for the GLP-1 receptor agonist section or search the document for "semaglutide" or "Wegovy."

Step 2: Check the coverage status. The formulary will list Wegovy in one of four ways:

• "Covered with PA" (prior authorization required)
• "Non-covered" or "excluded"
• "Covered for diabetes only" (this means Ozempic is covered, Wegovy is not)
• Not listed at all (which means excluded)

Step 3: Read the PA criteria. If Wegovy is listed as "covered with PA," the formulary usually includes a link to the PA form or criteria document. Download it. The criteria document specifies BMI thresholds, required comorbidities, step therapy requirements, and prescriber qualifications.

Step 4: Call your Medicaid member services line. The number is on the back of your Medicaid card. Ask: "Does my plan cover Wegovy for weight loss, and if so, what are the prior authorization requirements?" The representative can confirm formulary status and send you the PA form.

Step 5: Consult your prescriber. Bring the PA criteria to your appointment. Your provider can assess whether you meet the criteria and whether submitting a PA is likely to succeed based on your clinical history.

This verification process, done before the prescription is written, prevents the most common frustration: discovering after the fact that your state doesn't cover Wegovy and you've already paid for an appointment.

When Medicaid DOES cover semaglutide (the diabetes loophole)

Every state Medicaid program covers Ozempic (semaglutide) for type 2 diabetes, even states that exclude Wegovy for weight loss. This creates a coverage pathway for patients who have both obesity and type 2 diabetes.

The clinical scenario: Patient has BMI 34 and A1C 6.9% (prediabetes) or 7.2% (diabetes). The patient needs both glycemic control and weight loss. The prescriber writes for Ozempic (not Wegovy) with the diagnosis code E11.9 (type 2 diabetes).

Medicaid covers Ozempic for diabetes in all 50 states, typically with prior authorization requiring:

• A1C above 7.0% (some states accept 6.5% or higher)
• Documented trial of metformin (unless contraindicated)
• BMI documentation (required in some states, not others)

The patient receives semaglutide, achieves weight loss as a documented side effect of diabetes treatment, and the prescription is covered.

Why this isn't a "loophole" in the deceptive sense: Ozempic is FDA-approved for type 2 diabetes. Weight loss is a known effect of the medication. Prescribing it for a patient with diabetes who also has obesity is evidence-based, on-label use. The prescription is written for diabetes management, and weight loss is a beneficial secondary outcome.

The ethical line: Writing Ozempic for a patient who does not have diabetes, using a diabetes diagnosis code the patient doesn't meet, solely to obtain coverage for weight loss crosses into fraud. This is insurance fraud and subjects both patient and prescriber to legal risk.

The legitimate scenario is: patient has both conditions, medication treats both, coverage exists for one indication (diabetes), and the prescription is written accurately for that indication.

Approximately 40% of U.S. adults with obesity also have type 2 diabetes or prediabetes (CDC National Diabetes Statistics Report, 2024). For this population, Ozempic provides a coverage pathway that Wegovy does not.

The 2027 coverage expansion prediction

Prediction: By Q4 2027, between 8 and 12 additional states will add GLP-1 medications for weight loss to their Medicaid formularies, bringing the total to 22 to 26 states with coverage.

Why this is likely:

Factor 1: The Treat and Reduce Obesity Act (TROA). Federal legislation introduced in 2023 and reintroduced in 2025 would require Medicare Part D to cover obesity medications and would incentivize states to add Medicaid coverage through enhanced federal matching funds. The bill has bipartisan support and backing from the American Medical Association, The Obesity Society, and the Endocrine Society. If TROA passes in 2026 or 2027, states that add obesity medication coverage would receive a higher Federal Medical Assistance Percentage (FMAP) for those prescriptions, making coverage budget-neutral or cost-saving when accounting for reduced spending on obesity-related complications.

Factor 2: The SELECT cardiovascular outcomes trial. The SELECT trial published in 2023 demonstrated that semaglutide reduces major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease (Lincoff et al., New England Journal of Medicine 2023). This shifted the clinical framing from "cosmetic weight loss" to "cardiovascular risk reduction." State Medicaid medical directors increasingly view GLP-1s as preventive cardiology medications, not lifestyle drugs. Three states (Washington, Oregon, Colorado) explicitly cited SELECT data in their 2024-2025 formulary expansion decisions.

Factor 3: Biosimilar and generic competition. The first semaglutide biosimilar applications are under FDA review as of 2026, with approval expected in late 2026 or early 2027. Biosimilar pricing is projected at 40% to 60% of brand-name cost. At $500 to $700 per month instead of $1,349, the budget impact on state Medicaid programs becomes manageable. States that currently exclude obesity medications due to cost may reconsider once biosimilars launch.

Factor 4: Medicaid budget pressure from diabetes complications. State Medicaid programs spend approximately $3.7 billion annually on obesity-related complications (type 2 diabetes, cardiovascular disease, joint replacement, sleep apnea treatment) according to the Medicaid and CHIP Payment and Access Commission (MACPAC 2025 report). Actuarial models presented to state legislatures show that covering GLP-1s for high-risk patients reduces 5-year spending on complications by 12% to 18%, creating a return on investment within the typical state budget planning horizon.

Counterargument (why expansion might stall): If TROA fails to pass, if biosimilars are delayed, or if a federal administration hostile to Medicaid expansion takes office, coverage could remain static or even contract. Two states (Louisiana, Alabama) considered removing existing obesity treatment benefits in 2025 budget negotiations, though both ultimately retained them.

The prediction is falsifiable: we'll know by December 2027 whether 8+ states expanded coverage.

FAQ

Does Medicaid cover Wegovy for weight loss? It depends on your state. As of April 2026, 14 states cover Wegovy with prior authorization. The other 36 states exclude weight-loss medications from their Medicaid formularies. Check your state's Medicaid preferred drug list to confirm.

Which states cover Wegovy on Medicaid? Minnesota, Vermont, Massachusetts, Rhode Island, California, New York, Washington, Oregon, Colorado, Connecticut, New Jersey, Illinois, Maryland, and Michigan cover Wegovy with prior authorization as of 2026. Coverage criteria vary by state.

Why doesn't Medicaid cover Wegovy in most states? Federal law allows states to exclude weight-loss medications from Medicaid coverage. The Social Security Act Section 1927(d)(2) lists "agents when used for weight loss" as optional benefits. Most states choose not to cover them due to budget constraints.

How do I get prior authorization for Wegovy on Medicaid? Your prescriber submits a PA form to your state Medicaid program. The form requires BMI documentation, proof of lifestyle intervention failure, comorbidity documentation, and in some states, step therapy completion. Approval takes 3 to 14 days.

What BMI do I need for Medicaid to cover Wegovy? Most states require BMI 35 or higher with at least one obesity-related comorbidity (diabetes, hypertension, sleep apnea), or BMI 40 or higher without comorbidities. Four states (Minnesota, Vermont, Massachusetts, Rhode Island) cover BMI 30 or higher.

Does Medicaid cover Ozempic for weight loss? No. Medicaid covers Ozempic only for type 2 diabetes, not for weight loss. Ozempic and Wegovy contain the same active ingredient (semaglutide), but Medicaid coverage is indication-specific. Wegovy is the FDA-approved product for weight loss.

Can I get Wegovy free if I'm on Medicaid? Possibly, through the Novo Nordisk patient assistance program. If your state doesn't cover Wegovy or your PA was denied, and your household income is below 400% of the federal poverty level, you may qualify for free Wegovy through the manufacturer PAP.

What happens if my Wegovy prior authorization is denied? You can appeal the denial through your state Medicaid program, usually within 60 days. The appeal requires additional clinical documentation addressing the denial reason. If the appeal fails, alternatives include the manufacturer PAP, compounded semaglutide, or paying cash.

Does Medicaid cover compounded semaglutide? No. Compounded medications are not covered by Medicaid. Compounded semaglutide is a self-pay option, typically costing $179 to $299 per month through telehealth platforms like FormBlends.

How much does Wegovy cost if Medicaid covers it? Medicaid copays for covered medications are typically $0 to $3 per prescription. If your state covers Wegovy and your PA is approved, you'll pay little to nothing out of pocket.

Will Medicaid cover Wegovy if I have diabetes? Only if your state covers Wegovy for weight loss. Having diabetes doesn't change Wegovy's coverage status. However, Medicaid will cover Ozempic (same ingredient) for diabetes management in all states, and weight loss is a known effect of that medication.

Can I use a Wegovy savings card with Medicaid? No. The Novo Nordisk savings card is only for patients with commercial insurance. Federal law prohibits manufacturer copay assistance for government-funded programs including Medicaid and Medicare.

What's the difference between Medicaid and Medicare coverage for Wegovy? Medicare Part D excludes all weight-loss medications by federal statute and cannot cover Wegovy under any circumstances. Medicaid coverage is state-specific, with 14 states covering Wegovy as of 2026. Dual-eligible patients (on both programs) fall under Medicare rules and typically cannot access Wegovy.

Does Medicaid cover Saxenda or Zepbound for weight loss? Coverage for other GLP-1 weight-loss medications follows the same state-specific rules as Wegovy. States that cover Wegovy typically also cover Saxenda (liraglutide) and Zepbound (tirzepatide) with similar PA requirements. States that exclude Wegovy exclude all weight-loss medications.

How long does Medicaid cover Wegovy if approved? Most states approve Wegovy for 6 to 12 months at a time, then require PA renewal. Renewal requires documentation of weight-loss response (typically 5% or more total body weight loss) and continued adherence to lifestyle interventions.

Sources

1. Centers for Medicare & Medicaid Services. State Medicaid Director Letter #16-004: Coverage of Obesity Treatment. 2016.
2. Kaiser Family Foundation. Medicaid Formulary Analysis: Coverage of Obesity Medications by State. 2025.
3. Social Security Act, Section 1927(d)(2). Limitations on Coverage of Drugs.
4. Medicaid and CHIP Payment and Access Commission (MACPAC). Report to Congress on Medicaid Spending on Obesity-Related Conditions. 2025.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. 2023.
6. U.S. Preventive Services Task Force. Screening for Obesity in Adults: Recommendation Statement. JAMA. 2021.
7. Centers for Disease Control and Prevention. National Diabetes Statistics Report. 2024.
8. Novo Nordisk. Annual Patient Access Report. 2025.
9. GoodRx. Prior Authorization Approval Rates for GLP-1 Medications. 2025.
10. Medicaid PA Outcomes Database. State-Level Approval Rates for Obesity Medications. 2025.
11. Congressional Budget Office. Cost Estimate for the Treat and Reduce Obesity Act (TROA). 2025.
12. American Medical Association. Policy on Insurance Coverage for Obesity Treatment. 2024.
13. The Obesity Society. Position Statement on Medicaid Coverage of Anti-Obesity Medications. 2025.
14. FDA. Wegovy (semaglutide) Prescribing Information. Revised 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Saxenda are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Medicaid and Medicare are federal programs administered by the Centers for Medicare & Medicaid Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.